Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $61.86 | $18.77 | 229.56% | 257.75x | 18.66x | 18.90x | 50.66x | 1.22x | $41.15M | 0.76% | $108.58M | 1.23 | $5.46B | 101.92 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $301.98 | $96.73 | 212.20% | 69.26x | 40.95x | 9.36x | 37.49x | 1.42x | $641.34M | 1.60% | $1.08B | 8.09 | $41.58B | 44.97 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.16 | $2.90 | 112.44% | 88.00x | 51.55x | 3.34x | 81.74x | 0.84x | $47.52M | 4.53% | $13.01M | 0.08 | $1.21B | 22.65 | ||
| CORT | CORCEPT THERAPEUTICS INC | $69.49 | $19.35 | 259.17% | 151.07x | 132.72x | 9.44x | 11.69x | 1.42x | $119.79M | 1.65% | $637.99M | 6.11 | $7.36B | -1,072.06 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $48.38 | $17.78 | 172.04% | 49.37x | 37.89x | 4.91x | 6.15x | 1.34x | $164.23M | 4.44% | $605.69M | 7.92 | $3.54B | 31.76 | ||
| KRYS | KRYSTAL BIOTECH INC | $309.03 | $98.21 | 214.65% | 39.87x | 38.22x | 21.69x | 7.14x | 1.89x | $237.38M | 2.62% | $1.28B | 43.59 | $8.62B | 40.28 | ||
| ADMA | ADMA BIOLOGICS INC | $7.98 | $10.77 | -25.87% | 11.57x | 8.04x | 3.69x | 4.74x | 0.39x | $107.90M | 5.73% | $390.33M | 1.65 | $1.91B | 8.62 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $11.59 | $16.70 | -30.58% | 5.65x | 24.66x | 5.53x | 3.33x | 0.71x | $56.42M | 8.33% | $205.80M | 3.52 | $590.70M | 4.08 | ||
| OMER | OMEROS CORP | $11.04 | $15.94 | -30.74% | 8.49x | -28.99x | 80.00x | -12.62x | 0.43x | -$94.78M | -11.94% | -$63.33M | -0.88 | $1.11B | 12.25 | ||
| RPRX | ROYALTY PHARMA PLC | $55.76 | $40.95 | 36.17% | 29.19x | 10.46x | 9.98x | 3.23x | 0.63x | $2.34B | 9.61% | $9.94B | 22.75 | $40.48B | 34.79 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $57.29 | $41.92 | 36.65% | 40.92x | 14.42x | 3.40x | 1.78x | 0.58x | $767.06M | 6.96% | $6.21B | 32.27 | $9.43B | 19.55 | ||
| HALO | HALOZYME THERAPEUTICS INC | $66.54 | $72.40 | -8.09% | 22.48x | 8.03x | 5.21x | 35.93x | 0.41x | $667.65M | 8.49% | $219.64M | 1.86 | $9.73B | 15.59 | ||
| VCEL | VERICEL CORP | $33.33 | $9.38 | 255.31% | 77.51x | 69.14x | 5.79x | 4.78x | 1.63x | $47.49M | 2.81% | $356.23M | 7.02 | $1.69B | 41.75 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $231.96 | $98.25 | 136.10% | 29.36x | 25.74x | 16.80x | 4.66x | 1.44x | $122.22M | 2.65% | $997.32M | 50.16 | $4.99B | 22.10 | ||
| ASND | ASCENDIS PHARMA A | $224.11 | $86.01 | 160.56% | 23.75x | 18.04x | 13.67x | 24.25x | 2.21x | $52.94M | 0.38% | $574.09M | 9.24 | $14.30B | 153.35 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $236.49 | $50.05 | 372.51% | 503.17x | 9.16x | 3.30x | 3.27x | 1.72x | $1.30B | 8.87% | $4.53B | 73.22 | $18.40B | 27.25 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.83 | $5.89 | -51.94% | 10.48x | 4.14x | 2.65x | 3.10x | 0.22x | $7.24M | 4.45% | $52.93M | 0.92 | $110.21M | 7.11 | ||
| TGTX | TG THERAPEUTICS INC | $37.94 | $19.12 | 98.45% | 11.78x | 25.28x | 7.82x | 9.96x | 7.71x | -$14.19M | -0.26% | $583.13M | 4.04 | $6.12B | 40.77 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $31.59 | $36.81 | -14.19% | 12.49x | 8.61x | 2.03x | 2.01x | 0.47x | $341.79M | 18.71% | $910.35M | 15.75 | $1.40B | 5.90 | ||
| TECH | BIO-TECHNE CORP | $51.68 | $15.80 | 227.13% | 72.79x | 26.28x | 6.67x | 3.88x | 1.49x | $269.60M | 3.34% | $2.09B | 13.34 | $8.17B | 31.92 | ||
| UTHR | UNITED THERAPEUTICS CORP | $556.82 | $253.96 | 119.26% | 19.02x | 19.16x | 7.64x | 4.01x | 2.01x | $1.02B | 4.20% | $5.90B | 135.66 | $22.36B | 13.05 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $447.54 | $174.27 | 156.81% | 26.31x | 22.87x | 9.31x | 5.87x | 1.88x | $3.71B | 3.26% | $19.36B | 76.20 | $110.08B | 20.41 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.86 | $2.53 | 52.86% | 16.08x | 16.31x | 2.37x | 3.73x | 1.09x | $4.11M | 1.32% | $82.33M | 1.03 | $243.45M | 11.46 | ||
| EXEL | EXELIXIS INC | $50.48 | $31.67 | 59.40% | 16.18x | 15.32x | 5.49x | 6.55x | 1.18x | $917.69M | 7.04% | $1.94B | 7.49 | $12.63B | 11.96 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.23 | $15.30 | 104.17% | 17.25x | 16.23x | 6.40x | 3.77x | 1.96x | $208.13M | 5.45% | $1.01B | 8.28 | $3.07B | 9.16 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $614.78 | $454.70 | 35.20% | 14.45x | 13.00x | 4.29x | 2.05x | 0.94x | $4.11B | 6.43% | $31.42B | 302.15 | $64.20B | 11.17 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.11 | $1.79 | 18.01% | 11.11x | 9.71x | 2.20x | 2.53x | 0.96x | $13.00M | 7.73% | $67.23M | 0.84 | $136.78M | 6.13 | ||
| VCYT | VERACYTE INC | $46.34 | $12.67 | 265.80% | 41.75x | 41.18x | 6.80x | 2.75x | 2.40x | $155.34M | 4.21% | $1.34B | 16.90 | $3.47B | 30.18 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $17.87 | $4.72 | 278.33% | 29.78x | 5.13x | 0.86x | 1.25x | 4.17x | $109.24M | 5.82% | $1.51B | 14.34 | $2.46B | 29.72 | ||
| INCY | INCYTE CORP | $96.74 | $67.91 | 42.45% | 13.27x | 12.28x | 3.60x | 3.44x | 1.17x | $1.45B | 7.52% | $5.62B | 28.21 | $15.90B | 8.50 | ||
| MDXG | MIMEDX GROUP INC | $3.68 | $1.60 | 129.53% | 17.52x | -51.54x | 1.40x | 2.26x | 2.72x | $69.36M | 12.69% | $242.94M | 1.64 | $405.94M | 7.45 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.